Clinical trial · Interventional
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
NCT06165874CI-TRIAL-00072159unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to establish and optimize the imaging method of \[68Ga\]Ga-NOTA-RW102, as well as its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent was evaluated in patients with non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [68Ga]Ga-NOTA-RW102 PET Imaging | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- non-small cell lung cancer
- description
- Patients were recruited in the Department of Thoracic Surgery
- interventionNames
- Radiation: [68Ga]Ga-NOTA-RW102 PET Imaging
Primary outcomes (1)
- measure
- Calculation and comparison of [68Ga]Ga-NOTA-RW102 radioactivity concentrations in focal and non-focal tissues
- timeFrame
- 90mins from time of injection
- description
- Assessment of the efficacy of \[68Ga\]Ga-NOTA-RW102 in the diagnosis and differential diagnosis of non-small cell lung cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with PD-L1-positive non-small cell lung cancer 1. Age between 18 and 65 years old, gender is not limited. 2. Patients with CT findings that can be occupied on the lung with a diameter greater than 1cm or more who have not undergone surgery. 3. Lung cancer patients with a clinical diagnosis of positive PD-L1 expression; 4. Written informed consent must be signed by the subject or his/her legal guardian or caregiver. 5. Willingness and ability to cooperate with all programs of this study. Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from the study: 1. Severe hepatic and renal insufficiency; 2. Targeted therapy prior to radiotherapy or PET/CT scan. PD-L1 expression in existing lesions was assessed by immunohistochemistry using antibody clone 22C3. Renal function: serum creatinine less than or equal to the upper limit of the normal range; 3. Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. 4. History of serious surgery in the last month. 5. Those who have participated in other clinical trials during the same period.
References
Publications (1)
- DERIVEDZhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, Younis MH, Lin W, Zhao H, Wang C, Liu Q, Engle JW, Rasaee MJ, Guan Y, Huang G, Liu J, Cai W, Xie F, Wei W. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer. 2024 Apr 5;12(4):e008794. doi: 10.1136/jitc-2024-008794. PMID 38580333